Pediatrix Medical Group, Inc.
NYSE:MDMedical - Care Facilities
-$0.48 today
- Market cap
- $2.41B
- Beta
- 0.70
- P/E (TTM)
- 11.0
- EPS (TTM)
- $2.10
Volume 0.64M
Average 0.82M
MD Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Pediatrix Medical Group, Inc.NYSE: MD
Cash & Equivalents · Q3 FY2026 · quarter ended Sep 2026
Cash & equivalents falls 8.3% from a year ago
Cash & equivalents stood at $311.92M at the end of Q3 FY2026, down 8.3% from a year earlier and up 8.0% from the prior quarter. Over 3 fiscal years it compounded at +236.8% a year.
Context
- Cash & equivalents amounted to 14.6% of total assets at the end of Q3 FY2026, down 0.9 pp from a year earlier.
- Cash & equivalents increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -8.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 375.24M USD
- Year-over-year change
- +63.2%
- 4-year CAGR
- -0.8%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 375.24M | +63.2% |
| FY2024 | 2024-12-31 | 229.94M | +213.9% |
| FY2023 | 2023-12-31 | 73.26M | +645.7% |
| FY2022 | 2022-12-31 | 9.82M | -97.5% |
| FY2021 | 2021-12-31 | 387.39M | — |
Cash & Equivalents vs competitors
How MD compares with its peers on the latest reported figures
- MD's Sep 2026 cash & equivalents of $311.92M is the 4th highest of the 11 companies compared; the peer median is $180.58M.
- Its year-over-year change of -8.3% is the 9th highest of 11, against a peer median of +29.4%.
- Cash & equivalents amounts to 14.6% of total assets for MD, versus a peer median of 9.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $1.46B | +116.5% | -6.7% | 10.9% | |
ARDTArdent Health Partners, LLC | Mar 2026 | $609.69M | +23.2% | +15.9% | 11.6% |
| Mar 2026 | $478.38M | +85.0% | +14.2% | 20.3% | |
| Sep 2026 | $311.92M | -8.3% | +236.8% | 14.6% | |
| Jun 2026 | $225.94M | +19.6% | +31.8% | 10.4% | |
| Oct 2026 | $197.84M | +35.6% | +115.9% | 9.0% | |
| Sep 2026 | $163.31M | +37.6% | +10.9% | 2.9% | |
| Jun 2026 | $99.57M | +9.2% | +0.7% | 6.8% | |
GRDNGuardian Pharmacy Services, Inc. | Jun 2026 | $89.81M | +377.3% | +376.4% | 20.2% |
| Sep 2026 | $66.8M | -48.9% | +23.7% | 3.2% | |
| Mar 2026 | $25.68M | -51.7% | -35.3% | 0.4% | |
| Peer median (excluding MD) | $180.58M | +29.4% | +15.1% | 9.7% | |
Competitors are the stored peer set for MD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 387.39M | 9.82M | 73.26M | 229.94M | 375.24M |
| Short-term Investments | 99.72M | 93.24M | 104.49M | 118.57M | 124.48M |
| Net Receivables | 316.02M | 296.79M | 279.88M | 272.6M | 242.31M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 18.9M | 13.26M | 12.31M | 5.09M | 8.88M |
| Total Current Assets | 840.56M | 427.99M | 483.45M | 639.61M | 763.51M |
| Property, Plant & Equipment (Net) | 135.62M | 140.21M | 145.93M | 78.44M | 73.51M |
| Goodwill | 1.51B | 1.53B | 1.38B | 1.24B | 1.26B |
| Intangible Assets | 21.57M | 18.49M | 21.24M | 11.6M | 16.86M |
| Long-term Investments | 0 | 0 | 0 | 0 | 20.8M |
| Tax Assets | 88.34M | 105.93M | 102.85M | 103.86M | 73.92M |
| Other Non-current Assets | 131.03M | 123.18M | 82.17M | 76.6M | 37.36M |
| Total Non-current Assets | 1.88B | 1.92B | 1.74B | 1.51B | 1.48B |
| Total Assets | 2.72B | 2.35B | 2.22B | 2.15B | 2.25B |
| Account Payables | 36.65M | 31.86M | 34.59M | 46.43M | 37.22M |
| Short-term Debt | 0 | 12.5M | 12.5M | 18.75M | 38.4M |
| Tax Payables | 46.07M | 51.25M | 38.7M | 37.62M | 984K |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 94.63M |
| Total Current Liabilities | 427.37M | 426.98M | 388.95M | 434.11M | 458.91M |
| Long-term Debt | 1B | 627.65M | 611.59M | 593.57M | 594.64M |
| Deferred Tax Liabilities | 41.41M | 33.64M | 34.31M | 34.25M | 57.02M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 313.43M | 315.04M | 281.84M | 290.34M | 243M |
| Total Non-current Liabilities | 1.4B | 1.03B | 981.8M | 953.65M | 921.93M |
| Total Liabilities | 1.83B | 1.46B | 1.37B | 1.39B | 1.38B |
| Common Stock | 864K | 829K | 840K | 859K | 830K |
| Retained Earnings | (155.39M) | (89.06M) | (149.47M) | (248.54M) | (83.15M) |
| Accumulated OCI | 1.32M | (3.74M) | (2.21M) | (1.07M) | 610K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 205K | 0 | 0 | 0 | 0 |
| Total Equity | 896.69M | 891.63M | 849.06M | 764.94M | 865.85M |
| Total Debt | 1.07B | 717.08M | 701.65M | 662.31M | 660.3M |
| Net Debt | 678.44M | 707.26M | 628.39M | 432.37M | 285.06M |
Pediatrix Medical Group, Inc.
NYSE:MD
Intrinsic Alpha fair value
Locked
Current Price
$30.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.